Antidepressants are widely prescribed among women to treat depression and anxiety disorders, but studies of their effects on gynecological cancer risk are sparse. We assessed associations between various antidepressants and risk of epithelial ovarian cancer. By using Danish nationwide registers, we identified all women (cases) aged 30-84 years with incident epithelial (serous, endometrioid, clear cell or mucinous) ovarian cancer during 2000-2011 (n 5 4,103) and matched each case to 20 population controls (n 5 58,706) by risk-set matching. Data on drug use (including tricyclic and related antidepressants, selective serotonin reuptake inhibitors, other antidepressants, and potential confounder drugs), medical and reproductive history and socioeconomic parameters, were obtained from nationwide registries. We used conditional logistic regression models to estimate adjusted odds ratios (ORs) and two-sided 95% confidence intervals (CIs) for epithelial ovarian cancer associated with antidepressive drug use. Compared with non-use, use of selective serotonin reuptake inhibitors was associated with a decreased risk of ovarian cancer (OR, 0.85; 95% CI, 0.74-0.96), whereas the associations for other antidepressants were close to unity [tricyclic and related antidepressants: OR, 0.99 (95% CI, 0.78-1.26); other antidepressants: OR, 1.05 (95% CI, 0.76-1.46)]. For individual types of SSRI, reduced ORs were observed for citalopram OR, 0.78 (95% CI, 0.66-0.93), paroxetine 0.79 (95% CI, 0.56-1.12) and sertraline 0.80 (95% CI, 0.60-1.08). Among postmenopausal women, the inverse association was restricted to users of menopausal hormone therapy. In conclusion, use of selective serotonin reuptake inhibitors was associated with a decreased risk of epithelial ovarian cancer; thereby implying potential chemopreventive properties of these drugs.
Ovarian cancer is the leading cause of death among gynaecological malignancies 1 and thus identification of factors influencing the carcinogenesis of this disease would have major public health implications. Antidepressants are widely prescribed among women to treat depression and anxiety disorders, and often as chronical therapy. Some studies have suggested that antidepressants are carcinogenic, 2, 3 however, the evidence is inconsistent, and other studies have suggested that some antidepressants possess antineoplastic properties. [4] [5] [6] Only few studies have examined the association between use of antidepressants and risk of ovarian cancer. In 1995, Harlow et al. 7 reported that antidepressant use was associated with an increased risk of ovarian cancer, but the association was only found for antidepressants with effects on dopamine and/or norepinephrine receptors; and not for drugs affecting serotonin receptors. 8 Later studies have not supported such association pattern, [9] [10] [11] [12] however, these studies had limited ability to assess associations with use of serotonin reuptake inhibitors.
Selective serotonine reuptake inhibitors (SSRIs) are the newest generation of antidepressants and these agents have gradually replaced tricyclic and related antidepressants (TCAs) as the primary drugs of choice for treatment of depressive disorders. 13, 14 The widely use of antidepressants and their unresolved association with ovarian cancer risk prompted us to examine the association between use of SSRIs or other antidepressants and ovarian cancer risk, overall and for specific histological types, using Danish nationwide highquality registry data.
Methods
Our study was designed as a nested case-control study of population-based registry data in the entire Danish female population aged 30-84 (1.4 million women). We obtained data from six nationwide registry sources: The Danish Cancer Registry, 15 National Prescription Registry, 16 National Patient Registry, 17 Danish Education Registers, 18 Danish Birth Registry 19 and Danish Civil Registration System. 20 All data sources were linked by means of the unique civil registration number assigned to all Danish citizens. The study design has previously been described in detail. 21 
Selection of case patients and population controls
Eligible case subjects were all women with a first diagnosis of histologically verified epithelial ovarian cancer during 2000-2011. The diagnoses were coded in the Cancer Registry according to the International Classification of Diseases, (ICD) Tenth Revision (ICD-10: C56) and the ICD for Oncology (ICD-O-1-3) for histological type (serous, mucinous, endometrioid or clear cell). 21 Cases were required to be 30-84 years of age at ovarian cancer diagnosis and resident in Denmark at the start of the National Prescription Register (January 1995) and at the date of diagnosis (index date). We also required cases to have no history of cancer (except nonmelanoma skin cancer) prior to the ovarian cancer diagnosis. For each case, using risk set sampling, 17, 22 we selected 15 female age-matched controls (61 month), applying the same selection criteria as for cases and additionally requiring that controls had no history of bilateral oophorectomy before the index date (i.e., the date of diagnosis for the corresponding case). Thus, cases were eligible as controls prior to their cancer diagnosis, i.e., in the risk set until date of ovarian cancer.
Assessment of antidepressant use
We identified prescriptions of antidepressants redeemed by cases and controls from the Danish Prescription Registry, which holds information on all prescriptions dispensed in Denmark since 1995. The registry includes the type of drug according to the Anatomical Therapeutic Chemical (ATC) Classification System, 23 quantity dispensed and date of dispensing. For each prescription, the quantity of drug is given as the strength and number of the pharmaceutical entity (e.g., tablet) and number of packages, as well as the defined daily doses (DDDs) in each package. 23 We defined antidepressants as the ATC group N06A, except N06AX12 which is used mainly for smoking cessation. Antidepressants were categorized according to (1) tricyclic and related antidepressants, (2) SSRIs and (3) other antidepressants.
We defined use of antidepressants as two or more prescriptions on separate dates and non-use as fewer than two prescriptions. Use of antidepressants from more than one of the above antidepressant classes was defined as mixed use and analyzed separately. Use of antidepressants within 1 year prior to index date was disregarded to reduce possible reverse causality. 22 We defined the duration of use as the period from the first to the last prescription plus 60 days and categorized the duration into <5 years and 5 years. Intensity of use was defined as the cumulative number of defined daily doses (DDDs) divided by the duration of use in days. We used the distribution among controls to define cutoff values for the estimated average dose of antidepressant per day into approximate tertiles (low-, medium, high intensity; DDDs/ day) for each of the three major classes of antidepressants Finally, we identified the most frequently prescribed individual antidepressant drugs, i.e., drugs with 10 or more exposed cases.
Potential confounders
We based the a priori selection of potential confounders on knowledge from the current literature and availability of data in nationwide prescription, patient and education registries. The main analyses were adjusted for age and calendar year (by risk-set matching); medical histories of infertility(yes/no), endometriosis (yes/no), chronic obstructive pulmonary disease (COPD) (yes/no), diabetes (yes/no), tubal ligation (yes/ no), hysterectomy (yes/no); parity (0, 1, 2, 3) and use (2 prescriptions: yes/no) of paracetamol, aspirin, non-aspirin NSAID (NA-NSAID), statins, postmenopausal hormone therapy (HT), hormonal contraceptives (HC); and highest achieved education (basic/vocational; higher, unknown).
Statistical analyses
We used conditional logistic regression to estimate odds ratios (OR) and 95% confidence intervals (CIs) for ovarian cancer associated with use of antidepressants adjusted for age and calendar year (by design) and multivariable adjusted OR by the above mentioned confounders. In further models, we performed analyses stratified according to antidepressant What's new? Antidepressants are widely prescribed among women to treat depression and anxiety disorders, but studies of their potential influence on gynecological cancer risk remain sparse. Here, the authors used Danish nationwide registers to assess associations between different types of antidepressants and ovarian cancer risk. For the first time, they found that selective serotonin reuptake inhibitors (SSRIs) decreased risk of epithelial ovarian cancer. Other antidepressants were not associated with ovarian cancer, suggesting not only a diverse influence of antidepressants on cancer risk but also chemopreventive properties of SSRIs. Among postmenopausal women, the inverse association was restricted to users of menopausal hormone therapy.
class, individual drug use and by the duration and intensity of antidepressant use.
We repeated the analyses stratified by age at index date as a proxy for menopausal status (<50 years; 50 years) and calendar year (2000-2004; 2005-2011) and tested for effect modification. In sensitivity analyses, we incorporated mixed use of antidepressants in the analyses for the individual antidepressant classes. Finally, complying with the risk-set sampling, a subpopulation of women ever exposed to antidepressants was established, thereby diminishing the influence of depression itself; rather than the influence of treatment. Thus, in direct comparison, SSRI use was tested against tricyclic and related antidepressant use. Post-hoc analyses assessed use of hormonal contraception or postmenopausal hormone therapy as potential effect measure modifier. All analyses were performed with the statistical software R, version 3.0.2 (R development Core Team, 2013).
According to the Danish Research Ethics Committee Law ( § 8, Result section), ethical approval is not required for registry-based studies in Denmark. 
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Results
We identified 4,103 women with epithelial ovarian cancer (n 5 2,731 serous, n 5 650 endometrioid, n 5 459 mucinous and n 5 263 clear cell tumours) and 58,706 female population controls. Characteristics of cases and controls are presented in Table 1 . Cases were less likely to have used oral contraceptives and paracetamol and more likely to have used postmenopausal hormone therapy and infertility treatment. Finally, more cases were nulliparous. The overall prevalence of antidepressants use was 15% among cases and 17% among controls. Among controls, citalopram was the most commonly prescribed antidepressant drug (7.6%) followed by setraline (2.8%), fluoxetine (2.3%) and amitriptyline (2.2%). The corresponding prevalence estimates were slightly lower among cases. A total of 4,6% of the women had used different types of antidepressants.
Use of any type of antidepressants was associated with a 14% reduction in risk of epithelial ovarian cancer (OR, 0.86; 95% CI, 0.79-0.95). A similar inverse association with epithelial ovarian cancer risk was observed for use of SSRIs (OR, 0.85; 95% CI, 0.74-0.96), whereas ORs were close to unity for use of TCA or other antidepressants ( Table 2) .
Use of the most commonly prescribed antidepressant citalopram was associated with a decreased odds ratio of 0.78 (95% CI, 0.66-0.93) for epithelial ovarian cancer, and we also observed reduced ORs for paroxetine (0.79; 95% CI, 0.56-1.12) and sertraline (0.80; 95% CI, 0.60-1.08), although not being statistically significant. In contrast, the ORs for escitalopram and fluxetine were close to unity (Table 2) . Except for citalopram, the OR estimates for individual SSRIs were based on relatively small numbers.
No consistent associations were found between use of SSRI and non-SSRI antidepressants, respectively, and risks of the various histological types of epithelial ovarian cancer (Table 3) .
In analyses that defined antidepressant use according to duration and intensity of use, we found slightly decreasing ORs for epithelial ovarian cancer with increasing intensity of SSRI use, but with no apparent trend in ORs according to duration of SSRI use (Table 4, Supporting Information Tables  S1 and S2 ). For TCA and related antidepressants, we found no consistent risk variations with either intensity or duration of use (Table 4, Supporting Information Tables S1 and S2) . Tests for trends in ORs were all statistically insignificant.
Supplemental analyses
In direct comparison of SSRI use with use of tricyclic and related antidepressants, we observed a 24% reduction in risk of epithelial ovarian cancer (OR: 0.76; 95% CI, 0.53-1.07).
Adjustment for potential confounders had only limited influence on the estimated ORs.
When we included mixed use of antidepressants in the exposure groups, the results were similar to those of the main analyses (Supporting Information Table S5 ). No substantial effect measure modification was found by age or calendar year (i.e., assessing a longer exposure history among those women followed from 2005) (Supporting Information  Tables S3 and S4 ). Hormonal contraception use among women younger than 50 years did not modify the associations assessed. However, a possible effect measure modification by menopausal hormone therapy was found among women above 50 years of age. Among SSRI users, those who had ever used menopausal hormone therapy had a OR for ovarian cancer of 0.70 (95% CI, 0.56-0.87), whereas nonusers of menopausal hormone therapy exhibited a OR of 1.01 (95% CI, 0.83-1.22). No apparent effect measure modification by menopausal hormone therapy was observed among TCA users.
Discussion
In this nationwide study, we found that use of SSRIs was associated with a reduced risk of epithelial ovarian cancer, whereas use of TCA or other antidepressants did not influence ovarian cancer risk. There was a tendency towards decreasing risk of ovarian cancer with increasing intensity of SSRI use, but not with increasing duration of SSRI use. We found no clear pattern in risk estimates according to histological type of epithelial ovarian tumours. For individual types of SSRI, we found an 20% reduction in ovarian cancer risk associated with use of citalopram, the most commonly prescribed antidepressant, and similar risk reductions for paroxetine and sertraline use, although the latter associations were limited by low statistical precision. Experimental studies have suggested both tumour promoting and inhibiting effects of various antidepressants for various cancer types. 5, 6 A possible explanation for a reduced risk of ovarian cancer associated with use of SSRIs is induction of apoptosis. In one study, fluoxetine was demonstrated to induce apoptosis in the ovarian carcinoma cell line OVCAR-3. 24 Other studies have shown that sertraline and paroxetine can inhibit HT29 cells and induce alterations in apoptosis-related proteins, stimulating tumour cell programmed death. 25 Citalopram has also been suggested to control tumour growth by reducing the malignant cell cycle 26 and to activate the immune system leading to apoptosis in tumour cells. 6 To our knowledge the present study is the first to report a reduced risk of ovarian cancer associated with use of SSRIs and to assess associations with individual antidepressant drugs. Although one case-control study involving 563 cases reported an increased risk of ovarian cancer with certain types of psychotropic treatments, no association was found with drugs that worked through the serotonin or serotonine/norepinephrine pathways. 8 SSRIs as well as some of the commonly prescribed tricyclic and related antidepressants, act through these pathways supporting both our data and prior studies indicating no influence of TCA on ovarian cancer risk. Most previous studies of antidepressant use and ovarian cancer risk have focused on TCA. [9] [10] [11] An exception is the study by Morrman et al.
11 in which SSRI use was the dominant exposure. However, the study was based on self-reported use of antidepressants and consequently potential exposure misclassification might explain the neutral association between SSRI use and ovarian cancer risk observed in that study. 11 The strengths of our study include its nationwide design with a large study population and use of high-quality registry data with accurate and continuously updated data on ovarian The main limitation of our study was our inability to account comprehensively for the influence of depression besides that of antidepressant therapy. However, since depression-or health behaviour associated with depressionhas been associated with an increased risk of ovarian cancer, 27 this is unlikely to explain the inverse association between SSRI use and ovarian cancer risk observed in our study. Moreover, the fact that we found a reduced risk of ovarian cancer with use of SSRIs, but not with use of TCA or other antidepressants suggests that our results were not systematically biased by unknown or insufficiently measured confounding factors. Still, we cannot exclude that the specific indications for use of SSRI and TCA may have influenced differentially the associations for SSRI and TCA use. TCAs are used predominantly for manifest depression, whereas SSRIs are also used for variety of other or "off-label" indications. While depression may be associated with an increased risk of ovarian cancer, 27 no such evidence exists for other or 'off-label' indications for use of SSRIs. Assuming TCAs are more often prescribed for treatment of depression than SSRIs, this would draw any inverse associations for ovarian cancer with antidepressant use towards unity notably for TCA use.
A potential misclassification of users of antidepressants caused by symptoms of a yet-undiagnosed ovarian cancer was reduced by applying a 1-year lag period. Non-adherence to the medication may underestimate the associations assessed, since the users (those redeeming prescriptions) would then also include some women who were "truly" nonusers. However, we do not expect that women continue to redeem (and pay) for prescriptions that they do not use. In addition, women having a "high intensity" of use (DDD/day) over a long time are bound to have redeemed several prescriptions to be classified as a "high intensity" user (Table 4) . Table 4 suggests that the conclusion about differences between TCA and SSRI is less likely to be confounded by non-adherence, since this finding was evident also for longterm and "high intensity" users. On the other hand, nonadherence would give a less precise measurement of the true duration of use, which could underestimate the associations between duration of use and ovarian cancer risk. Thus, the lack of an association between duration of SSRI use and ovarian cancer risk might be explained by measurement error of duration of use. We only had information on redeemed prescriptions on antidepressants from the year of 1995, which could also have caused a misclassification of users into the non-exposed group leading to a potential bias towards the unity. However, in additional analyses we allowed for a longer exposure history (i.e., the women were followed from year 2005 and onwards; which allows for 5 additional years of exposure history). These risk estimates were not stronger than those from the main analysis indicating that lack of medical history before 1995 is unlikely to cause an underestimation of our results. Finally, despite controlling for most known risk factors for ovarian cancer -and in addition, education-, we cannot exclude residual confounding by low socioeconomic position or obesity. However, since both of these factors has been found associated with an increased risk of ovarian cancer. 28, 29 -and are expected to be more common among users of antidepressants-, which would generate a bias towards the null. We observed suggestive effect measure modification with use of menopausal hormone therapy for SSRI use, but not for TCA use. Among postmenopausal women with a previous history of menopausal hormone therapy, we found a 30% reduced risk for ovarian cancer associated with any SSRI use, whereas the association was neutral among postmenopausal women without such history. Whether this reflects true effect measure modification by postmenopausal hormone therapy use or chance is not possible to address further in the current study. In conclusion, we found a reduced risk of ovarian cancer associated with use of SSRI driven by citalopram, paroxetine and sertraline. If the inverse association between SSRI use and ovarian cancer risk proves to be causal, and not only restricted to women taking hormone therapy, this would have major implications for the indications and prescribing of SSRI and TCA.
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